RVMD News

Join Class Action to Recover Losses from Erasca, Inc. (ERAS) – Contact Levi & Korsinsky Before August 10, 2026

ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Contact Levi & Korsinsky by August 10, 2026 to Join Class Action Against Erasca, Inc. (ERAS)

Join Class Action to Recover Losses From Erasca, Inc. (ERAS) - Contact Levi & Korsinsky Before August 10, 2026

Robbins LLP Urges ERAS Stockholders Who Lost Money Investing in Erasca, Inc. to Contact The Firm For Information About Leading The Class Action

ERAS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline

Did You Lose Money on Erasca, Inc. (ERAS)? Levi & Korsinsky Urges Investors to Act Before August 10, 2026

ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer